TSE:I Intellipharmaceutics International (I) Stock Price, News & Analysis → Trending Stocks Sent To You In Real Time (From Huge Alerts) (Ad) Free I Stock Alerts Add Compare Share Share Today's Range N/A50-Day RangeC$3.23▼C$3.2352-Week Range N/AVolume7,625 shsAverage Volume16,872 shsMarket CapitalizationC$97.40 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Intellipharmaceutics International alerts: Email Address Ad DTIWarning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation here About Intellipharmaceutics InternationalIntellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.Read More Ad Behind the MarketsThe AI Defense Stock Set to SoarTo protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.Here's how you can invest >>> I Stock News HeadlinesFebruary 19, 2024 | theglobeandmail.comIntelliPharmaCeutics Intl: Top 10 Undervalued Biotechnology Industry Stocks (IPCI)January 3, 2024 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc up on Wednesday (IPCI)March 28, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.December 7, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc up on Tuesday (IPCI)October 16, 2023 | msn.comIntellipharmaceutics International GAAP EPS of -$0.06October 13, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc down on Friday (IPCI)July 6, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc down on Wednesday (IPCI)June 29, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc down on Tuesday (IPCI)March 28, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…June 13, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc down on Monday (IPCI)April 18, 2023 | finance.yahoo.comIntellipharmaceutics International Inc. (I4AA.F)April 7, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc flat on Wednesday (IPCI)April 5, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc flat on Monday (IPCI)April 4, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc flat on Friday (IPCI)February 7, 2023 | yahoo.comIntellipharmaceutics Provides Update on Management Cease Trade Order Application and Anticipates Cease Trade OrderJanuary 13, 2023 | finance.yahoo.comIntellipharmaceutics International Inc. (IPCIF)August 30, 2022 | thestreet.comChanges at the Top for Endo Could Benefit Its Smaller PartnersAugust 23, 2022 | reuters.comIntellipharmaceutics International IncJuly 23, 2022 | finanznachrichten.deIntellipharmaceutics International Inc.: Intellipharmaceutics Announces Second Quarter 2022 ResultsJuly 21, 2022 | finance.yahoo.comIntellipharmaceutics Announces Second Quarter 2022 ResultsJuly 15, 2022 | ca.finance.yahoo.comStocks in play: Intellipharmaceutics International Inc.April 14, 2022 | finanznachrichten.deIntellipharmaceutics International Inc.: Intellipharmaceutics Announces First Quarter 2022 ResultsApril 14, 2022 | stockhouse.comIntellipharmaceutics Announces First Quarter 2022 ResultsFebruary 28, 2022 | finanznachrichten.deIntellipharmaceutics International Inc.: Intellipharmaceutics Announces Fiscal Year 2021 ResultsJanuary 13, 2022 | finanznachrichten.deIntellipharmaceutics International Inc.: Intellipharmaceutics Mourns the Death of Valued Board Member Kenneth Eugene KeirsteadJanuary 7, 2022 | nasdaq.comIntellipharmaceutics International Inc (IPCIF)October 15, 2021 | finance.yahoo.comIntellipharmaceutics Announces Third Quarter 2021 ResultsSee More Headlines Receive I Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intellipharmaceutics International and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Next Earnings (Estimated)6/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorBusiness Services Industry Wireless Telecommunications Sub-IndustryN/A Current SymbolTSE:I CUSIPN/A CIKN/A Webwww.intelsat.com Phone+1-416-7983001FaxN/AEmployees1,195Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares30,156,000Free FloatN/AMarket CapC$97.40 million OptionableNot Optionable BetaN/A 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesIsa Odidi Ph.D.Chairman of the Board, Chief Executive OfficerAmina Odidi Ph.D.President, Chief Operating Officer, DirectorAndrew PatientChief Financial OfficerJohn N. AllportVice President - Legal Affairs and Licensing, Secretary, DirectorPatrick N. Yat Ph.D.Vice President - Pharmaceutical Analysis and ChemistryKenneth KeirsteadIndependent DirectorBahadur MadhaniIndependent DirectorEldon R. Smith M.D. (Age 75)Independent Director More ExecutivesKey CompetitorsCIBT Education GroupTSE:MBANeuLionTSE:NLNZCL CompositesTSE:ZCLReitmansTSE:RETCO2 SolutionsCVE:CSTView All Competitors I Stock Analysis - Frequently Asked Questions When is Intellipharmaceutics International's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 4th 2024. View our I earnings forecast. What other stocks do shareholders of Intellipharmaceutics International own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intellipharmaceutics International investors own include QuickLogic (QUIK), VBI Vaccines (VBIV), NeuLion (NLN), Micron Technology (MU), Mallinckrodt (MNK), Intellipharmaceutics International (IPCIF), Fitbit (FIT), Clean Commodities (CLE), Calithera Biosciences (CALA) and BlackBerry (BB). How do I buy shares of Intellipharmaceutics International? Shares of I stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:I) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryUrgent: Protect Your Investments from a Chinese InvasionBehind the MarketsSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellipharmaceutics International Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.